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Cite This: ACS Omega 2020, 5, 1430−1438 Read Online
ACCESS Metrics & More Article Recommendations *sı Supporting Information
ABSTRACT: A series of substituted sulfonanilide analogs were
prepared and evaluated as novel potent inhibitors of SH2 domain-
containing inositol polyphosphate 5′-phosphatase 2 (SHIP2).
SHIP2 has been shown to be a new attractive target for the
treatment of insulin resistance in type 2 diabetes mellitus (T2D),
which can lead to life-threatening diabetic kidney disease (DKD).
Amongst the synthesized compounds, the two most promising
candidates, 10 and 11, inhibited SHIP2 significantly. Additionally,
these compounds induced Akt activation in a dose-dependent
manner, increased the presence of glucose transporter 4 at the
plasma membrane, and enhanced glucose uptake in cultured
myotubes in vitro at lower concentrations than metformin, the most widely used antidiabetic drug. These results show that the novel
SHIP2 inhibitors have insulin sensitizing capacity and provide prototypes for further drug development for T2D and DKD.
■ INTRODUCTION
Diabetes mellitus is one of the major health concerns in the
world today. Globally, more than 425 million people were
suffering from this metabolic disorder in 2017, and the
predicted number of affected individuals in the future is
dramatically higher, expected to reach 629 million by 2045.1
Customarily, diabetes is divided into type 1 and type 2 diabetes
mellitus (T1D and T2D) in addition to some rare forms of the
disease.2 T2D, accounting for the majority of the patients, is
characterized by insulin resistance (the inability of the cells to
respond to insulin) and inadequate production of insulin.2
Severe long-term complications of T2D include cardiovascular
diseases, diabetic kidney disease (DKD), diabetic retinopathy,
and diabetic neuropathy.3,4 Recently, a new classification of
diabetes mellitus has been proposed, dividing the patients into
five subgroups based on six clinical variables.5 Interestingly,
patients with severe insulin resistance were observed to have
the highest risk of DKD, the severe and potentially life-
threatening complication of diabetes.5 This observation raises
the interest to design novel insulin sensitizers that could be
used to treat T2D and DKD.
At the cellular level, insulin resistance in muscle, adipose,
and kidney glomerular epithelial cells may be caused by a
defect in glucose uptake as a consequence of decreased activity
of the phosphatidyl inositol 3 kinase (PI3K)-mediated insulin
signaling pathway or impaired translocation of the insulin-
responsive glucose transporter 4 (GLUT4) to the plasma
membrane.6−8 The insulin signaling cascade is activated when
insulin binds to its receptor on the plasma membrane,
triggering a cascade of intracellular events that result in the
activation of downstream kinase Akt and glucose uptake into
cells.6 SHIP2, SH2 domain-containing inositol polyphosphate
5′-phosphatase 2, has been identified as a 5′-lipid phosphatase
that suppresses insulin signaling by hydrolyzing the PI3K
product PtdIns(3,4,5)P3 (PIP3) to PtdIns(3,4)P2 (PIP2),
resulting in a reduced activation of Akt and diminished
glucose uptake.9,10 Both genetic and experimental studies link
SHIP2 to metabolic disorders. Polymorphisms in INPPL1, the
gene encoding SHIP2, are associated with hypertension, the
metabolic syndrome, and T2D.11−15 In rodent models of
insulin resistance and T2D, SHIP2 has been shown to be
upregulated in insulin responsive tissues, including the skeletal
muscle, adipose tissue, and kidney glomeruli,16,17 apparently
contributing to insulin resistance. In addition, a transgenic
mouse model overexpressing SHIP2 under a modified β-actin
promoter impairs glucose tolerance and insulin sensitivity.13
These data indicate that SHIP2 is an excellent drug target to
ameliorate insulin resistance and treat T2D and DKD.
Only a few compounds that inhibit SHIP2 have been
described. The known inhibitors belong to the thienylamide-
b a s e d , 1 8 , 1 9 p y r i d i n y l a m i d e - b a s e d , 2 0 o r
(benzenesulfonylamino)benzamide-based21 compound classes.
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Furthermore, only a few studies describe the effects of these
inhibitors in animal models or cultured cells.19−21 We recently
observed that metformin, a biguanide, binds to SHIP2 directly
and inhibits its catalytic activity,22 thus supporting SHIP2 as a
target to treat T2D. Apart from metformin, none of the other
thus far described SHIP2 inhibitors are in clinical use. We have
now designed a sulfonanilide-based compound library of new
SHIP2 inhibitors and tested their potency to inhibit SHIP2 in
vitro. In addition, using cultured myotubes, we tested whether
the two most potent inhibitors enhance the activation of the
insulin signaling pathway and increase glucose uptake.
■ RESULTS
Chemistry. Various novel sulfonanilide SHIP2 inhibitor
candidates (1−12) were synthesized by stirring together
different sulfonyl chlorides with various anilines or N-
methylanilines under basic conditions in acetonitrile at room
temperature. The solid sulfonanilide products were obtained in
good yields (49−68%) and high purity (>98%) after
recrystallization (Scheme 1).
Inhibition of SHIP2 Activity by Sulfonanilides. To
investigate the ability of the sulfonanilides to inhibit the
activity of SHIP2, we divided them to three groups based on
three different anilines: N-methylaniline, 2-bromo-4-fluoroani-
line, and 2,4-difluoro-N-methylaniline. The N-methylaniline-
based sulfonanilides 1−6 inhibited SHIP2 activity by only 3−
15% (Table 1). Replacing N-methylaniline with 2-bromo-4-
fluoroaniline resulted in the p-tolyl compound 7, which
inhibited SHIP2 activity by 17%. On the other hand, a slight
decrease in the inhibition was seen for the trifluorophenyl
compound 8 and furyl compound 9, which inhibited SHIP2
activity by 10 and 9%, respectively. In contrast, the 2-thienyl-
substituted analog 10 showed an increase in the SHIP2
inhibition, with a very promising inhibition efficiency of 45%.
Alternatively, modifying the aniline in compound 8 to 2,4-
difluoro-N-methylaniline gave an increase in the inhibition for
the pentafluorinated compound 11, which similarly inhibited
SHIP2 activity by 45%. The 2-thienyl compound 12 with 2,4-
difluoro-N-methylaniline was almost inactive. The IC50 values
for the best two SHIP2-inhibiting sulfonanilides, 10 and 11,
were 41.2and 7.07 μM, respectively (Table 1).
Cytotoxicity of Sulfonanilides 10 and 11. To further
evaluate the properties of the sulfonanilides 10 and 11, we
measured whether they affect the viability of L6 myotubes
using the alamarBlue cell viability assay. Sulfonanilides 10 and
11 showed no or very little effect on cell viability up to 200 μM
concentration (Figure 1). When the concentration was
increased to 300 μM, sulfonanilide 10 decreased the viability
of myotubes by only 7% whereas sulfonanilide 11 reduced cell
Scheme 1. Synthesis of SHIP2 Sulfonanilide Inhibitorsa
aReagents and conditions: sulfonyl chloride (1 equiv), aniline or N-methylaniline derivative (1 equiv), pyridine (∼6 equiv), dry MeCN (5 mL),
room temperature, 35−210 min. *Yield is calculated after recrystallization from MeOH or EtOH. **Purity is determined using HPLC by careful
integration of the peak areas.
Table 1. IC50 Values and Maximal Inhibition of
Sulfonanilide Analogs 1−12
entry IC50 (μM) max. inhibition (%)
1 NAa 6 ± 2.8
2 NAa 10 ± 7.2
3 >50 15 ± 1.6
4 >50 12 ± 4.0
5 NAa 3 ± 1.5
6 >50 11 ± 2.2
7 >50 17 ± 2.1
8 NAa 10 ± 5.1
9 NAa 9 ± 3.0
10 41.2 45 ± 17
11 7.07 45 ± 0.7
12 NAa 5 ± 1.7
aIC50 values not assigned (NA) for compounds with inhibition equal
or lower than 10%.
Figure 1. Cytotoxicity of sulfonanilides 10 and 11. Sulfonanilide 10
was not cytotoxic up to 200 μM concentration. Both sulfonanilides 11
and 10 affected very little the cytotoxicity at high concentrations
(tested up to 300 μM).
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viability by 24% at this concentration (Figure 1). This indicates
that sulfonanilides 10 and 11 are not toxic to myotubes.
Sulfonanilides 10 and 11 Activate the Insulin
Signaling Pathway. As the phosphorylation of Akt indicates
the activation of the insulin signaling pathway, we next
determined the effect of sulfonanilides 10 and 11 on insulin-
induced Akt phosphorylation in L6 myotubes. For this,
myotubes were pretreated for 15 min with 1, 10, 25, or 50
μM sulfonanilide 10 or 11 followed by stimulation with 10 nM
insulin for an additional 15 min. Akt was activated with 10 and
25 μM sulfonanilide 10 and 1 and 10 μM sulfonanilide 11
(Figure 2). Neither sulfonanilide 10 nor 11 activated Akt at 50
μM concentration in this short-term treatment. The level of
total Akt did not change under any of the conditions (Figure
2). These data indicate that sulfonanilides 10 and 11 increase
insulin-induced phosphorylation of Akt in a dose-dependent
manner in a short-term treatment.
Sulfonanilides 10 and 11 Enhance Glucose Uptake.
To determine the functional effects of sulfonanilides 10 and
11, we evaluated their ability to enhance glucose uptake into
L6 myotubes stably overexpressing HA-tagged GLUT4 glucose
transporter (referred to as L6-GLUT4 myotubes).18 For this,
L6-GLUT4 myotubes were treated with 50 μM sulfonanilide
10 or 11 for 20 h, whereafter the cells were treated or not with
100 nM insulin, followed by measuring the cellular uptake of
radioactively labeled 2-deoxyglucose. For comparison, we
carried out glucose uptake assays with metformin, the
previously characterized SHIP2 inhibitor,22 using the same
50 μM concentration of metformin. Under serum starvation,
both 10 and 11 alone increased glucose uptake by 18−19%.
With insulin stimulation, 10 and 11 increased glucose uptake
by 30 and 23%, respectively, compared to control cells
stimulated with insulin (Figure 3). Metformin, on the other
hand, did not enhance glucose uptake at this concentration
with or without insulin stimulation (Figure 3). These data
indicate that sulfonanilides 10 and 11 enhance insulin-induced
glucose uptake into L6-GLUT4 myotubes at 50 μM
concentration whereas metformin does not.
Sulfonanilides 10 and 11 Increase the Presence of
GLUT4 at the Plasma Membrane. To further confirm that
sulfonanilides 10 and 11 affect the insulin signaling pathway,
we investigated their effect on GLUT4 translocation, using L6-
GLUT4 myotubes. The HA-tag is located in the extracellular
domain of GLUT4, which allows quantifying the presence of
GLUT4 on the plasma membrane by surface labeling with an
antibody against the HA-tag. In control myotubes without
sulfonanilide treatment, insulin stimulation increased the
relative amount of GLUT4 on the plasma membrane by 16%
compared to myotubes without insulin treatment (Figure 4).
Treatment of myotubes with sulfonanilide 10 led to a 4%
increase in the amount of GLUT4 on the plasma membrane
without insulin stimulation (Figure 4). The increase with
insulin stimulation was 26% compared to control cells without
insulin stimulation and 10% compared to control cells treated
with insulin. Sulfonanilide 11 increased the presence of
GLUT4 on the plasma membrane by 8% without insulin
stimulation. The increase with insulin stimulation was 15%
compared to control cells without insulin stimulation, but
when compared to control cells with insulin stimulation, there
was no increase (Figure 4).
Docking Studies of Sulfonanilide 11. To investigate the
binding mode of our most potent inhibitor, sulfonanilide 11,
we docked 11 onto the phosphatase domain of SHIP2 (PDB
ID: 4A9C; crystal structure described by Mills et al.23) (Figure
5). In our simulations, the sulfonyl group binds tightly between
the four amino acid units Arg 611, Tyr 661, Arg 682, and Asn
Figure 2. Sulfonanilides 10 and 11 activate Akt in L6 myotubes. L6 myotubes serum starved for 20 h were treated with sulfonanilide 10 or 11 (1−
50 μM) or vehicle (DMSO) for 15 min after which insulin (10 nM) was added for an additional 15 min. Activation of the insulin signaling pathway
was determined by analyzing the phosphorylation of Akt at Ser473 by quantitative Western blotting. (A, B) Quantification of protein levels of three
replicate Western blots of L6 myotubes treated with (A) 10 or (B) 11 and representative blots. Data are expressed as fold-change relative to the
vehicle, and values are mean ± SEM. Three experiments in which n = 3 for each condition. *p < 0.05, **p < 0.01.
Figure 3. Sulfonanilides 10 and 11 enhance glucose uptake in L6
myotubes. Glucose uptake in L6 myotubes overexpressing GLUT4
transporter was measured by a radioactive 2-deoxyglucose assay after
20 h serum starvation and inhibitor treatment (sulfonanilides 10 or
11, or metformin) and either with or without 15 min insulin
stimulation. Four experiments in which n = 4 for each condition. Data
are expressed as fold-change relative to the control (no inhibitor
treatment, no insulin), and values are mean ± STD. Statistical
significance denoted as: * = compared to control without insulin; # =
compared to control with insulin; **/## p ≤ 0.01, ***/### p ≤
0.001 (unpaired Student’s t-test).
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684 in SHIP2. The fluoride substituents are hydrogen bonded
to Arg 682 and Glu 473. Additionally, π-stacking is observed
from the phenyl ring to the Arg 682 unit.
■ DISCUSSION
We have designed and synthesized a series of sulfonanilide
derivatives that we analyzed for their potency to act as novel
SHIP2 inhibitors. Based on our in vitro analyses, we have
created two new nontoxic SHIP2 inhibitors that enhance
glucose uptake into cultured myotubes more potently than
metformin.
In our molecular library of 12 sulfonanilide derivatives,
based on three different anilines, we observed that combining a
highly fluorinated benzenesulfonyl chloride with 2,4-difluoro-
N-methylaniline as in 11 increases the ability of the
sulfonanilide to inhibit the activity of SHIP2 as measured by
using the purified SHIP2 phosphatase domain and malachite
green phosphate assay. Additionally, the 2-thienyl compound
12 with 2,4-difluoro-N-methylaniline was almost inactive
possibly due to blocking of the hydrogen bonding to the free
N−H group, therefore having a negative effect on the binding
mode. This result indicates that 2-bromo-4-fluoroaniline
should be preferably combined with a heteroarenesulfonyl
chloride as seen in 10, which increases the ability of the
compound to inhibit SHIP2. Consequently, sulfonanilides 10
and 11 were identified as the most potent SHIP2 inhibitors.
As SHIP2 hydrolyzes PIP3 to PIP2 and thereby reduces the
activation of Akt,9,10 SHIP2 inhibition is expected to lead to
the activation of Akt. In line with this, we observed that
sulfonanilides 10 and 11 increase the insulin-induced
phosphorylation of Akt, indicative of its activation, in a similar
manner as the previously characterized SHIP2 inhibitors
AS1949490, AS1938909, and N-[4-(4-chlorobenzyloxy)-
p y r i d i n e - 2 - y l ] - 2 - ( 2 , 6 - d ifluo ropheny l ) - a c e t am ide
(CPDA).18−20 Sulfonanilides 10 and 11 activated Akt in a
dose-dependent manner, with the lowest concentrations (10
and 25 μM for 10 and 1 and 10 μM for 11) enhancing Akt
phosphorylation in a short-term (30 min) treatment. The
highest concentration tested (50 μM) did not enhance Akt
activation in this short-term treatment, apparently indicative of
activation of a negative feedback loop abolishing Akt
activation. In the cell viability measurements using alamarBlue,
which measures cellular metabolism and cell viability,24,25 both
10 and 11 appeared to slightly enhance the metabolic activity
of the cells at 50 μM concentration. The highest concentration
of sulfonanilide 11 (300 μM) lowered cell viability by 24%
while 10 had only a minor effect on viability at this
concentration. This indicates that both 10 and 11 are well
tolerated by myotubes at their effective concentrations.
SHIP2 inhibition is expected to enhance the insulin-induced
increase in glucose uptake, and as expected, sulfonanilides 10
and 11 increased glucose uptake into myotubes after 20 h
treatment at 50 μM concentration. Metformin, the most widely
used antidiabetic drug, did not increase glucose uptake at this
concentration. We and others have previously shown that 2
mM metformin is necessary to increase glucose uptake into
myotubes.22,26 It may be that sulfonanilides 10 and 11 are
more potent than metformin in increasing glucose uptake, or
alternatively, 10 and 11 may be transported more efficiently
into cells than metformin. Metformin is internalized by organic
cation transporters (OCTs), the expression of which is lowered
in cultured cells in vitro compared to tissues in vivo, thus
leading to a low uptake of metformin in vitro.27 Previous
studies have shown that sulfonylureas bind to the sulfonylurea
receptor (SUR) subunit of the ATP-sensitive potassium
channel, also present in muscle cells.28 Apparently, sulfonani-
lides 10 and 11 are internalized in a similar manner by SUR,
but this requires further studies. Nevertheless, sulfonanilides
10 and 11 enhanced insulin-stimulated glucose uptake into
myotubes at a concentration ineffective for metformin.
An earlier study revealed that the sulfonylureas gliclazide and
glyburide increased glucose uptake independently of insulin by
increasing the content of glucose transporter 1 (GLUT1) at
the plasma membrane in L6 myotubes, with no effect on
GLUT4.29 Sulfonanilides 10 and 11 slightly increased the
presence of GLUT4 on the plasma membrane with or without
insulin stimulation, which may be due to increased exocytosis
or slower endocytosis of GLUT4 as a result of the treatment
with the sulfonanilides. This may explain at least partially the
increased glucose uptake seen with sulfonanilides 10 and 11.
On the other hand, the sulfonylureas glimepiride, gliquidone,
and glipizide have been shown to enhance insulin sensitivity of
3T3-L1 adipocytes by increasing the transcriptional activity of
the peroxisome proliferator-activated receptor γ (PPARγ),30 a
transcription factor that regulates lipid and glucose metabo-
lism.31 It thus appears that different sulfonylureas affect glucose
metabolism via different mechanisms, in addition to their
major function as enhancers of insulin secretion from
pancreatic β-cells.27
The new suggested classification of diabetes into different
subgroups based on specific clinical characteristics opens an
important avenue for developing new and more effective
individualized treatments as patients in different subgroups
have a differing risk of diabetic complications.5 Of special
Figure 4. Sulfonanilides 10 and 11 increase the presence of GLUT4
on the plasma membrane. HA-GLUT4 on the plasma membrane
(PM) was measured by On-Cell Western assay after 20 h treatment
with sulfonanilide 10 or 11 and either with or without 15 min insulin
stimulation. Four experiments in which n = 6−10 for each condition.
Data are expressed as fold-change relative to the control (no
sulfonanilide treatment, no insulin), and values are mean ± STD.
Statistical significance denoted as: * = compared to control without
insulin; # = compared to control with insulin; */# p ≤ 0.05, **/## p
≤ 0.01, ***/### p ≤ 0.001 (unpaired Student’s t-test).
Figure 5. Molecular docking analysis of sulfonanilide 11 onto the
binding pocket of the SHIP2 phosphatase domain (PDB ID: 4A9C).
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interest in terms of DKD is the subgroup of severely insulin
resistant patients.5 In our previous study, we found that SHIP2
activity is elevated in the kidney in patients with T2D receiving
other medication than metformin compared to people without
diabetes.22 We further found that metformin increases the
insulin sensitivity of peripheral tissues and protects from a
kidney injury by inhibiting the catalytic activity of SHIP2.22
Thus, new SHIP2 inhibitors that are more potent than
metformin in their insulin sensitizing capacity could provide
more effective treatment options for T2D and DKD and serve
as an alternative to metformin when its use is contraindicated.
In conclusion, our results show the potential of targeting
SHIP2 to develop new treatments for T2D. Here, we have
synthesized a molecular library of sulfonanilide derivatives and
established their capacity to act as novel SHIP2 inhibitors.
Among the compounds synthesized, 2′-bromo-4′-fluoro-2-
thiophenesulfonanilide (10) and 2′,4′-difluoro-N-methyl-
2,3,4-trifluorobenzenesulfonanilide (11) were identified as
the most potent SHIP2 inhibitors having insulin sensitizing
capacities. Therefore, these compounds serve as important
prototypes for the further development of new treatments for
T2D and DKD.
■ EXPERIMENTAL SECTION
Materials and Methods. Commercially purchased
reagents and solvents were used without further purification
if not otherwise stated. N-Methylaniline and 2-bromo-4-
fluoroaniline were distilled prior to use. The solvents were
dried in a VAC Vacuum Atmospheres Co. solvent purifier
system. The reactions were followed using Sigma-Aldrich
Supelco silica gel on TLC Al foils with fluorescent indicator
254 nm and using the Plate Express Advion MS (TLC-CMS)
instrument with APCI±-ionization. Column chromatography
was performed using VWR Chemicals silica gel 40−60 μm
with the eluent systems specified in the experiments. Melting
points were measured in one end open capillaries with a digital
melting point apparatus, Büchi B-545. 1H and 13C-NMR
spectra were recorded on a Varian UNITY INOVA 500
spectrometer (500 MHz 1H-frequency and 125 MHz 13C-
frequency) in CDCl3 (containing 0.03% tetramethylsilane,
TMS, as reference) or DMSO-d6 as a solvent at 27 °C. All the
chemical shifts are given in parts per million (ppm). IR spectra
were recorded using a Bruker ALPHA FT-IR spectrometer
with a platinum-ATR disc (Bruker Optics). High-resolution
mass spectrometry, HRMS, analyses were made using a Bruker
Micro-TOF time-of-flight mass spectrometer (Bruker Dal-
tonics) with positive electrospray ionization (ESI+). The
protonated molecular ion, [M + H+], or the corresponding
sodium salt, [M + Na + H+], was identified. All the measured
HRMS m/z-values were within a 5 ppm error margin.
The purity of the final products was determined using
reversed-phase high-performance liquid chromatography, RP-
HPLC. The purity of all compounds was above 98%,
determined by integration of the peak areas using an Agilent
1200 series LC-unit. The column used was a Waters Symmetry
RP-C18, 5 microns particle size, 4.6 mm × 250 mm. The
products were eluted with the MeCN/0.1% formic acid in
milli-Q water eluent mixture using a gradient method (55:45
0−4 min, 55:45 to 90:10 4−14 min, 90:10 to 55:45 14−19
min, 55:45 19−25 min). The flow rate was 1 mL min−1
(pressure ∼110 bar), and UV-wavelengths used were 254, 280,
and 265 nm. The column temperature was 40 °C, and the
injection volume was 10 μL. Elemental analyses were
performed on a vario MICRO cube elemental analyzer
(Elementar Analysensysteme GmbH, Hanau, Germany).
General Procedure for the Synthesis of Compounds
1−12. In our protocol for preparing the sulfonanilides, the
sulfonyl chloride (1 equiv) was dissolved in dry acetonitrile (5
mL) under argon atmosphere at room temperature. The
aniline or N-methylaniline (1 equiv) in pyridine (∼6 equiv)
was added to the sulfonyl chloride solution. The reaction was
stirred at room temperature under argon and monitored by
TLC and TLC-CMS until completion (35−270 min). The
reaction mixture was acidified with aq 2 M HCl solution and
extracted with ethyl acetate (6 × 5 mL). The organic layer was
separated, washed with 30 mL of water and 30 mL of aq sat
NaCl solution, dried over MgSO4, filtered, and evaporated.
The crude solid product was purified by recrystallization from
either methanol or ethanol (abs). The pure solid product was
filtered, dried, and characterized by spectroscopic methods.
N-Methylbenzenesulfonanilide (1). For full structural
characterization and chemical properties, see the Supporting
Information.
N-Methyl-p-toluenesulfonanilide (2). For full structural
characterization and chemical properties, the see Supporting
Information.
N-Methyl-2-naphthalenesulfonanilide (3). For full structural
characterization and chemical properties, see the Supporting
Information.
N-Methyl-2,3,4-trifluorobenzenesulfonanilide (4). White
needles; yield 57%; mp 104 °C (EtOH). 1H NMR (500
MHz, CDCl3): δH 7.43−7.38 (m, 1H), 7.34−7.26 (m, 3H),
7.19−7.16 (m, 2H), 7.01 (tdd, J = 9.01 Hz, 6.57 Hz, 2.10 Hz,
1H), 3.37 ppm (d, J = 1.96 Hz, 3H). 13C NMR (125 MHz,
CDCl3): δC 154.32 (ddd, 258.90 Hz, 9.80 Hz, 3.08 Hz, C−F),
148.98 (ddd, 260.00 Hz, 11.64 Hz, 4.08 Hz, C−F), 140.61 (dt,
256.68 Hz, 15.57 Hz, C−F), 140.58 (Cquat), 129.51, 128.13,
126.88, 125.73 (dd, 8.51 Hz, 4.40 Hz, C−Harom), 124.06 (ddd,
12.06 Hz, 4.06 Hz, 2.12 Hz, Cquat), 112.45 (dd, 17.94 Hz, 3.89
Hz, C−Harom), 38.84 ppm (d, J = 3.48 Hz, CH3). IR (cm−1): ν ̃
= 3064 (s; ν(C−Harom)), 2987 (s; ν(C−Haliph)), 2943 (s;
ν(C−Haliph)), 1603 (m), 1503 (m), 1455 (m), 1354 (s;
ν(SO2−N)), 1154 (s; ν(SO2−N)), 1123 (s; ν(C−F)), 1034
(s), 701 (s). HRMS (ESI): m/z calcd for C13H10F3NO2S + H
+
[M + H+]: 302.0457. Found: 302.0442. HPLC analysis:
retention time = 10.908 min, peak area, 100%. Elemental
analysis calcd (%) for C13H10F3NO2S: C 51.83, H 3.35, N
4.65, S 10.64. Found: C 51.76, H 3.37, N 4.69, S 10.63.
N-Methyl-3-furansulfonanilide (5). White needles; yield
53%; mp 100 °C (MeOH). 1H NMR (500 MHz, CDCl3):
δH 7.73 (s, 1H), 7.45 (t, J = 1.54 Hz, 1H), 7.35−7.26 (m, 3H),
7.21−7.19 (m, 2H), 6.34 (d, J = 1.54 Hz, 1H) 3.22 ppm (s,
3H). 13C NMR (125 MHz, CDCl3): δC 146.15 (CH−O),
144.52 (CH−O), 141.47 (Cquat), 129.21, 127.80, 126.82,
123.91 (Cquat), 109.24, 38.28 ppm (CH3). IR (cm
−1): ν ̃ = 3156
(s; ν(furan)), 3135 (s; ν(furan)), 3009 (s; ν(C−Harom)), 2980
(s; ν(C−Haliph)), 1595 (m), 1492 (s), 1369 (s; ν(SO2−N)),
1157 (s; ν(SO2−N)), 1130 (s), 1009 (s; ν(furan)), 870 (s,
ν(furan)), 816 (s). HRMS (ESI): m/z calcd for C11H11NO3S
+ H+ [M + H+]: 238.0532. Found: 238.0522. HPLC analysis:
retention time = 6.795 min, peak area, 98.2%. Elemental
analysis calcd (%) for C11H11NO3S: C 55.68, H 4.67, N 5.90, S
13.51. Found: C 55.42, H 4.68, N 5.92, S 13.50.
N-Methyl-2-thiophenesulfonanilide (6). For full structural
characterization and chemical properties, see the Supporting
Information.
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2′-Bromo-4′-fluoro-p-toluenesulfonanilide (7). For full
structural characterization and chemical properties, see the
Supporting Information.
2′-Bromo-4′-fluoro-2,3,4-trifluorobenzenesulfonanilide (8).
After work-up, the crude product was purified by column
chromatography on silica gel using n-hexane/dichloromethane
(1:1) followed by recrystallization. White solid; yield 50%; mp
83 °C (EtOH). 1H NMR (500 MHz, CDCl3): δH 7.62 (dd, J =
9.15 Hz, 5.24 Hz, 1H), 7.55 (tdt, J = 6.92 Hz, 3.20 Hz, 2.42
Hz, 1H), 7.23 (dd, J = 7.64 Hz, 2.81 Hz, 1H), 7.10 (bs, 1H,
N−H), 7.07−7.01 ppm (m, 2H). 13C NMR (125 MHz,
CDCl3): δC 160.28 (d, J = 251.44 Hz, C−F), 154.97 (ddd, J =
259.72 Hz, 10.11 Hz, 3.27 Hz, C−F), 149.11 (ddd, J = 260.99
Hz, 11.79 Hz, 4.05 Hz, C−F), 140.66 (dt, J = 257.88 Hz, 15.47
Hz, C−F), 130.19 (d, J = 3.70 Hz, Cquat), 125.53 (d, J = 8.66
Hz, C−H), 125.10 (dd, J = 8.80 Hz, 4.47 Hz, C−Harom),
124.90 (ddd, J = 11.13 Hz, 3.81 Hz, 1.66 Hz, Cquat), 120.26 (d,
J = 25.78 Hz, C−Harom), 117.09 (d, J = 9.80 Hz, Cquat), 116.06
(d, J = 22.28 Hz, C−Harom), 112.69 ppm (dd, J = 18.23 Hz,
3.84 Hz, C−Harom). IR (cm−1): ν ̃ = 3259 (s; ν(N−H)), 3088
(s; ν(C−Harom)), 1596 (m), 1487 (m), 1347 (s; ν(SO2−N)),
1168 (s; ν(SO2−N)), 1038 (s; ν(C−F)), 819 (s), 598 (s;
ν(C−Br)). HRMS (ESI): m/z calcd for C12H5BrF4NO2S + Na
+ H+ [M + Na + H+]: 405.9131. Found: 405.9119. HPLC
analysis: retention time = 10.377 min, peak area, 100%.
Elemental analysis calculated (%) for C12H5BrF4NO2S: C
37.52, H 1.57, N 3.65, S 8.35. Found: C 37.31, H 1.71, N 3.66,
S 8.38.
2′-Bromo-4′-fluoro-3-furansulfonanilide (9). White solid;
yield 49%; mp 126 °C (EtOH). 1H NMR (500 MHz,
CDCl3): δH 7.79 (dd, J = 1.73 Hz, 0.75 Hz, 1H), 7.67 (dd, J =
8.93 Hz, 5.33 Hz, 1H), 7.41 (t, J = 1.73 Hz, 1H), 7.24 (dd, J =
7.70 Hz, 2.88 Hz, 1H), 7.06 (ddd, J = 8.93 Hz, 7.84 Hz, 2.88
Hz, 1H), 6.88 (bs, 1H, N−H), 6.50 ppm (dd, J = 1.73 Hz, 0.75
Hz, 1H). 13C NMR (125 MHz, CDCl3): δC 160.12 (d, J =
251.01 Hz, C−F), 146.42 (CH−O), 144.94 (CH−O), 130.97
(d, J = 3.52 Hz, Cquat), 126.20 (Cquat), 125.33 (d, J = 8.87 Hz,
C−Harom), 120.08 (d, J = 25.88 Hz, C−Harom), 117.22 (d, J =
10.13 Hz, Cquat), 116.00 (d, J = 22.48 Hz, C−Harom), 108.55
ppm. IR (cm−1): ν ̃ = 3258 (s; ν(N−H)), 3147 (s; ν(furan)),
3129 (s; ν(furan)), 3092 (s; ν(C−Harom)), 1599 (m), 1485
(s), 1330 (s; ν(SO2−N)), 1194 (s; ν(SO2−N)), 1151 (s;
ν(C−F)), 1005 (s; ν(furan)), 872 (s, ν(furan)), 821 (s), 601
(s; ν(C−Br)). HRMS (ESI): m/z calcd for C10H6BrFNO3S +
Na + H+ [M + Na + H+]: 341.9206. Found: 341.9197. HPLC
analysis: retention time = 6.707 min, peak area, 100%.
Elemental analysis calcd (%) for C10H6BrFNO3S: C 37.52,
H 2.20, N 4.38, S 10.01. Found: C 37.46, H 2.17, N 4.48, S
10.17.
2′-Bromo-4′-fluoro-2-thiophenesulfonanilide (10). Off-
white solid; yield 51%; mp 109 °C (EtOH). 1H NMR (500
MHz, CDCl3): δH 7.70 (dd, J = 9.03 Hz, 5.37 Hz, 1H), 7.58
(dd, J = 4.99 Hz, 1.31 Hz, 1H), 7.45 (dd, J = 3.82 Hz, 1.31 Hz,
1H), 7.21 (dd, J = 7.70 Hz, 2.87 Hz, 1H), 7.07 (ddd, J = 9.03
Hz, 7.71 Hz, 2.87 Hz, 1H), 7.02 (dd, J = 4.99 Hz, 3.82 Hz,
1H) 6.88 ppm (bs, 1H, N−H). 13C NMR (125 MHz, CDCl3):
δC 160.23 (d, J = 251.00 Hz, C−F), 139.05 (Cquat), 133.34
(CH−S), 133.29, 130.98 (d, J = 3.27 Hz, Cquat), 127.74,
126.04 (d, J = 8.68 Hz, C−Harom), 119.97 (d, J = 26.14 Hz, C−
Harom), 117.81 (d, J = 9.93 Hz, Cquat), 115.99 ppm (d, J =
21.92 Hz, C−Harom). IR (cm−1): ν ̃ = 3257 (s; ν(N−H)), 3089
(s; ν(thiophene)), 1596 (m), 1483 (m), 1335 (s; ν(SO2−N)),
1156 (s; ν(SO2−N)), 1037 (s; ν(C−F)), 873 (s), 731 (s;
ν(thiophene)), 567 (s; ν(C−Br)). HRMS (ESI): m/z calcd for
C10H6BrFNO2S2 + Na + H
+ [M + Na + H+]: 357.8978.
Found: 357.8973. HPLC analysis: retention time = 8.024 min,
peak area, 99.6%. Elemental analysis calcd (%) for
C10H6BrFNO2S2: C 35.73, H 2.10, N 4.17, S 19.07. Found:
C 35.65, H 2.09, N 4.32, S 19.11.
2′,4′-Difluoro-N-methyl-2,3,4-trifluorobenzenesulfonanilide
(11). White solid; yield 58%; mp 106 °C (EtOH). 1H NMR
(500 MHz, CDCl3): δH 7.50−7.45 (m, 1H), 7.38 (td, J = 8.78
Hz, 5.87 Hz, 1H), 7.03 (tdd, J = 9.94 Hz, 4.66 Hz, 2.10 Hz,
1H), 6.89 (dddd, J = 8.78 Hz, 7.38 Hz, 2.80 Hz, 1.43 Hz, 1H),
6.80 (ddd, J = 10.61 Hz, 8.32 Hz, 2.80 Hz, 1H), 3.35 ppm (q, J
= 0.96 Hz, 3H). 13C NMR (125 MHz, CDCl3): δC 162.79 (dd,
J = 252.30 Hz, 11.78 Hz, C−F), 159.81 (dd, J = 254.44 Hz,
12.80 Hz, C−F), 154.53 (ddd, J = 259.26 Hz, 19.88 Hz, 2.82
Hz, C−F), 149.19 (ddd, J = 260.97 Hz, 11.52 Hz, 3.81 Hz, C−
F) 140.70 (dt, J = 241.16 Hz, 15.62 Hz, C−F), 133.23 (dd, J =
10.22 Hz, 2.51 Hz, C−Harom), 125.31 (dd, J = 8.67 Hz, 4.45
Hz, C−Harom), 124.94 (m, Cquat), 123.79 (dd, J = 12.21 Hz,
4.24 Hz, Cquat), 112.42 (d, J = 3.76 Hz, C−Harom), 112.26 (t, J
= 3.88 Hz, C−Harom), 105.25 (dd, J = 26.43 Hz, 23.67 Hz, C−
Harom), 38.75 ppm (t, J = 3.25 Hz, CH3). IR (cm
−1): ν ̃ = 3058
(s; ν(C−Harom)), 2987 (s; ν(C−Haliph)), 2957 (s; ν(C−
Haliph)), 1610 (m), 1505 (m), 1456 (m), 1358 (s; ν(SO2−N)),
1158 (s; ν(SO2−N)), 1124 (s; ν(C−F)), 1058 (s), 857 (s).
HRMS (ESI): m/z calcd for C13H7F5NO2S + Na + H
+ [M +
Na + H+]: 360.0088. Found: 360.0089. HPLC analysis:
retention time = 11.520 min, peak area, 99.7%. Elemental
analysis calcd (%) for C13H7F5NO2S: C 46.30, H 2.39, N 4.15,
S 9.51. Found: C 46.26, H 2.46, N 4.21, S 9.50.
2′,4′-Difluoro-N-methyl-2-thiophenesulfonanilide (12). Pale
yellow solid; yield 64%; mp 80 °C (EtOH). 1H NMR (500
MHz, CDCl3): δH 7.62 (dd, J = 5.04 Hz, 1.03 Hz, 1H), 7.45
(dd, J = 3.97 Hz, 1.03 Hz, 1H), 7.28 (td, J = 8.60 Hz, 5.95 Hz,
1H), 7.11 (dd, J = 5.04 Hz, 3.97 Hz, 1H), 6.87 (tdd, J = 8.19
Hz, 2.95 Hz, 1.55 Hz, 1H), 6.81 (ddd, J = 10.43 Hz, 8.60 Hz,
2.95 Hz, 1H), 3.25 ppm (d, J = 0.94 Hz, 3H). 13C NMR (125
MHz, CDCl3): δC 162.53 (dd, J = 251.61 Hz, 11.60 Hz, C−F),
159.75 (dd, J = 255.65 Hz, 12.68 Hz, C−F), 138.10 (Cquat),
132.86 (CH−S), 132.67, 132.43 (dd, J = 10.13 Hz, 2.68 Hz,
C−Harom), 127.71, 124.69 (dd, J = 11.73 Hz, 4.14 Hz, Cquat),
111.97 (dd, J = 22.30 Hz, 3.69 Hz, C−Harom), 105.28 (dd, J =
26.37 Hz, 23.92 Hz, C−Harom), 38.43 ppm (d, J = 3.62 Hz,
CH3). IR (cm
−1): ν ̃ = 3110 (s; ν(thiophene)), 3088 (s), 3058
(s; ν(C−Harom)), 1504 (m), 1349 (s; ν(SO2−N)), 1176 (s;
ν(SO2−N)), 1153 (s; ν(C−F)), 720 (s; ν(thiophene)), 683
(s). HRMS (ESI): m/z calcd for C11H8F2NO2S2 + Na + H
+
[M + Na + H+]: 311.9935. Found: 311.9942. HPLC analysis:
retention time = 8.888 min, peak area, 99.3%. Elemental
analysis calcd (%) for C11H8F2NO2S2: C 45.67, H 3.14, N
4.84, S 22.16. Found: C 45.56, H 2.95, N 4.96, S 22.25.
SHIP2 Activity Measurements. For the activity measure-
ments and other biological assays, sulfonanilides 1−12 were
dissolved in DMSO and then further diluted into indicated
concentrations in assay buffers or media. The capacities of 1−
12 to inhibit SHIP2 activity and the IC50 values of 1−12 were
measured using the recombinant SHIP2 phosphatase domain
and malachite green phosphate assay at the High Throughput
Biomedicine Unit (University of Helsinki, Finland). Different
concentrations of 1−12 were dispensed to 384-well plates after
which 100 ng of purified His-tagged recombinant SHIP2
phosphatase domain in reaction buffer (10 mM HEPES, pH
7.25, 6 mM MgCl2, 0.1% CHAPS, 250 mM sucrose and 0.25
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mM EDTA) was added, and the plates were incubated for 15
min at room temperature. The reaction was started by adding
7.5 μL of PI(3,4,5)P3 (Echelon Biosciences, Salt Lake City,
UT, USA) diluted in the reaction buffer (the final
concentration of PI(3,4,5)P3 per well was 100 μM in the
total volume of 15 μL), plates were incubated for 20 min at
room temperature, and 15 μL of BIOMOL green reagent
(Biomol, Plymouth Meeting, PA, USA) was added to wells.
After 25 min incubation at room temperature, the absorbance
was measured at 620 nm using a Pherastar FS plate reader
(BMG Labtech, Offenburg, Germany) (n = 3 for each
condition).
Cell Culture. Rat L6 myoblasts (American Type Culture
Collection, Manassas, Virginia, USA) and L6 myoblasts stably
overexpressing HA-tagged GLUT4 transporter (L6-GLUT4)
were grown in high glucose DMEM (Sigma-Aldrich)
supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO,
USA), glutamine (Lonza; Walkersville, MD, USA), and
penicillin−streptomycin (Sigma-Aldrich) at +37 °C in a
humidified 5% CO2 atmosphere. For differentiation, the FBS
concentration in the medium was lowered to 2%.
Cytotoxicity Assay. For cytotoxicity analyses, L6 myo-
blasts were seeded on 96-well plates, differentiated for 7 days
into myotubes, and incubated O/N with 0-300 μM
sulfonanilides after which 10 μL of alamarBlue cell viability
reagent (ThermoFisher Scientific, Waltham, MA, USA) was
added according to the manufacturer instructions. The
fluorescence was measured at 544/590 nm ± 20 nm using a
Hidex Sense microplate reader (Hidex, Turku, Finland) at 0
and 60 min time points after the addition of the alamarBlue
reagent, and the viability of the cells was calculated. The assay
was repeated three times (n = 4 for each condition).
Akt Activation Assay. To measure the Akt activation
(phosphorylation), L6 myoblasts were differentiated into
myotubes for 7 days, serum starved O/N, and treated with
0−50 μM sulfonanilides for 15 min after which 10 nM insulin
(Actrapid, Novo Nordisk, Bagsvaerd, Denmark) was added for
an additional 15 min. The cells were lysed in NP-40 buffer (1%
nonidet P-40, 20 mM Tris−HCl pH 7.4, 150 mM NaCl)
supplemented with phosphatase inhibitors (50 mM NaF and 1
mM Na3VO4) and protease inhibitor cocktail (cOmpletePro-
tease Inhibitor Coctail tablets, Roche Diagnostics GmbH,
Mannheim, Germany) and then immunoblotted as in
Tolvanen et al.32 Briefly, samples were separated in 8%
polyacrylamide gels and transferred onto PVDF membrane
(Immobilon-FL PVDF transfer membrane, Merck Millipore
Ltd., Tullagreen, Ireland). The membrane was blocked using
Odyssey blocking buffer (LI-COR, Lincoln, NE, USA) and
incubated with primary antibodies against pAkt (phospho-Akt,
Ser473, #9271, Cell Signaling Technology, Danvers, MA,
USA), Akt (pan-Akt, #281046, R&D Systems, Minneapolis,
MN, USA), and actin (A3853, Sigma-Aldrich) followed by
secondary antibodies (IRDye 800CW Donkey anti-Rabbit and
IRDye 680RD Donkey anti-Mouse, both from LI-COR,
Lincoln, NE, USA). Three individual assays were performed
(n = 3 for each condition).
Glucose Uptake Assay. Glucose uptake was measured by
a radioactive 2-deoxyglucose assay. L6 myotubes overexpress-
ing GLUT4 glucose transporter were differentiated for 8−9
days. Cells were serum-starved for 20 h supplemented with 50
μM of sulfonanilides 10 or 11, 50 μM of metformin.
Thereafter, cells were stimulated or not with 100 nM insulin
for 15 min at 37 °C in DMEM (without D-glucose, L-
glutamine, phenol red, and sodium pyruvate) (Gibco/Thermo
Fisher Scientific). The cells were exposed to 1 μCi/mL 2-
deoxy-D-[1, 2-3H(N)]-glucose (PerkinElmer, Waltham MA,
USA) for 5 min at 37 °C. Cells were lysed in 1% Triton X-100
in PBS, and the radioactivity of lysates was measured with a
Wallac 1450 Microbeta Trilux liquid scintillator and a
luminescense counter (PerkinElmer). Four independent
experiments were performed, with 4 technical replicates for
each condition.
On-Cell Western for HA-GLUT4. Differentiated L6-
GLUT4 myotubes cultured on 96-well plate were treated
with sulfonanilides 10 or 11 at 50 μM concentration for 20 h,
of which the last 4 h in a serum-free medium. The quiescent
cells were stimulated or not with 100 nM insulin for 15 min at
37 °C and fixed with 2% paraformaldehyde on ice for 5 min
followed by 20 min at room temperature. The cells were
incubated with a primary antibody against HA.11 epitope tag
(#901513, BioLegend, San Diego, CA, USA) diluted 1/100 in
50% Odyssey Blocking buffer (LI-COR) in PBS at room
temperature for 1 h, followed by incubation with a secondary
antibody (IRDye 800CW Donkey anti-Mouse, LI-COR) and
the nuclear marker DRAQ-5 (Thermo Fisher Scientific,
Rockford, IL, USA) at room temperature for 1 h. The
fluorescent signals were detected and quantified with an
Odyssey infrared imager (LI-COR). DRAQ-5 was used for
normalization. Four independent experiments were performed,
resulting in total in 30−34 replicates for each condition.
Statistical Analyses. Data are presented as means ± STD
or SEM of three or four independent experiments. Statistical
analyses were performed using an unpaired, two-tailed
Student’s t-test. P-values ≤0.05 were considered statistically
significant. IC50-values were calculated using GraphPad
Software, Inc., Prism version 6.05 (San Diego, CA, USA)
using four-parameter curve-fit.
Molecular Docking of Sulfonanilide 11 onto the
Structural Model of SHIP2. The crystal structure of the
phosphatase domain of human SHIP2 in complex with a ligand
biphenyl 2,3′,4,5′,6-pentakisphosphate was obtained from the
Protein Data Bank (PDB ID: 4A9C). The protein structure
was cleaned, hydrogens added, and solvent molecules removed
using Dassault System̀es BIOVIA, BIOVIA Discovery Studio,
client 2018, San Diego: Dassault System̀es, 2018, software.
Sulfonanilide 11 was prepared using a prepared ligand
function. The binding site in SHIP2 was designed as described
in Mills et al.23 Docking of 11 onto the model of SHIP2 was
performed using GOLD 5.7.1 with default parameters, and the
docking poses were analyzed visually and based on the
Goldscore Fitness values.
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Kristiina Wähälä − University of Helsinki, Helsinki,
Finland; orcid.org/0000-0003-4082-8622;
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.9b02944
ACS Omega 2020, 5, 1430−1438
1436
Phone: +358504487502; Email: kristiina.wahala@
helsinki.fi
Other Authors
Mika E. A. Berg − University of Helsinki, Helsinki,
Finland; orcid.org/0000-0002-1095-0179
Jette-Britt Naams − University of Helsinki, Helsinki,
Finland
Laura C. Hautala − University of Helsinki, Helsinki,
Finland
Tuomas A. Tolvanen − University of Helsinki, Helsinki,
Finland
Jari P. Ahonen − University of Helsinki, Helsinki, Finland
Sanna Lehtonen − University of Helsinki, Helsinki,
Finland; orcid.org/0000-0003-4189-2415
Complete contact information is available at:
https://pubs.acs.org/10.1021/acsomega.9b02944
Author Contributions
#J.-B.N. and L.C.H. contributed equally. M.E.A.B. and J.P.A.
synthesized and analyzed all the sulfonanilide inhibitors.
M.E.A.B. carried out the computational studies. J.-B.N.,
L.C.H., T.A.T., and S.L. carried out the biological testing of
the sulfonanilide inhibitors. M.E.A.B., J.-B.N., and K.W. wrote
the manuscript, and all co-authors corrected the manuscript.
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
Business Finland (to S.L. and K.W.) and the Jane and Aatos
Erkko Foundation (to S.L.) are thanked for financial support.
CSC Computer Service Center is acknowledged for providing
computer time.
■ REFERENCES
(1) IDF Diabetes Atlas; International Diabetes Federation, 8th Ed.,
2017, p. 9.
(2) American Diabetes Association. Diagnosis and Classification of
Diabetes Mellitus. Diabetes Care 2014, 37, S81−S90.
(3) Pratley, R. E. The Early Treatment of Type 2 Diabetes. Am. J.
Med. 2013, 126, S2−S9.
(4) Chatterjee, S.; Khunti, K.; Davies, M. J. Type 2 Diabetes. Lancet
2017, 389, 2239−2251.
(5) Ahlqvist, E.; Storm, P.; Kar̈aj̈am̈ak̈i, A.; Martinell, M.; Dorkhan,
M.; Carlsson, A.; Vikman, P.; Prasad, R. B.; Aly, D. M.; Almgren, P.;
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